Close Menu

NIPT

In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."

The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.

The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.

Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.

Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2019.

The notes will be sold at an initial effective conversion price of about $38.79 per share, approximately a 30 percent premium to Monday's $29.84 per share closing price.

The company is withdrawing its previous financial guidance for 2020, saying that it cannot predict the extent or duration of the impact of the COVID-19 pandemic.

Under the 2018 agreement, the companies had planned to develop cell-free DNA assays for prenatal screening using Qiagen's GeneReader sequencing system.

The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.

AdGeniX started distributing Yourgene's Iona test in France in 2015 and has rapidly grown sales for the test, a trend that is expected to continue.

Pages

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.